An update on the current and emerging pharmacotherapies for basal cell carcinomas
Expert Opin Pharmacother. 2023 Nov 14. doi: 10.1080/14656566.2023.2284351. Online ahead of print.ABSTRACTINTRODUCTION: Despite surgical approach is still the mainstay for basal cell carcinoma (BCC) management, several issues may limit the use of this technique, leading to the need for new treatments to offer patients a personalized approach.AREAS COVERED: A comprehensive review of the available and emerging pharmacologic strategies for BCC management including mechanisms of action, and potential adverse effects has been performed to provide with an up-to-date manuscript on the current treatment scenario of BCC. Globally, t...
Source: Expert Opinion on Pharmacotherapy - November 14, 2023 Category: Drugs & Pharmacology Authors: Alessia Villani Massimiliano Scalvenzi Giuseppe Micali Fabrizio Martora Francesco Cillo Flavia Raia Luca Potestio Source Type: research
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update
Expert Opin Pharmacother. 2023 Nov 13. doi: 10.1080/14656566.2023.2282673. Online ahead of print.ABSTRACTINTRODUCTION: Strong scientific evidence and large experience support the use of β2-agonists for the symptomatic alleviation of COPD. Therefore, there is considerable effort in discovering highly potent and selective β2-agonists.AREAS COVERED: Recent research on novel β2-agonists for the treatment of COPD. A detailed literature search was performed in two major databases (PubMed/MEDLINE and Scopus) up to September 2023."EXPERT OPINION: Compounds that preferentially activate a Gs- or β-arrestin-mediated signaling pat...
Source: Expert Opinion on Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Barbara Rinaldi Luigino Calzetta Paola Rogliani Mario Cazzola Source Type: research
Longitudinal efficacy of Ertugliflozin in type 2 diabetes: a meta-analysis of randomized controlled trials
CONCLUSION: Ertugliflozin showed clinical efficacy in improving glycemic control, fasting plasma glucose, body weight, and systolic blood pressure in T2DM patients over the studied time intervals compared to placebo.PMID:37955156 | DOI:10.1080/14656566.2023.2279100 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Parvej Khan Shubhashree Venkatesh Rizwana Parveen Pinki Mishra Seema Jain Nidhi Agarwal Source Type: research
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update
Expert Opin Pharmacother. 2023 Nov 13. doi: 10.1080/14656566.2023.2282673. Online ahead of print.ABSTRACTINTRODUCTION: Strong scientific evidence and large experience support the use of β2-agonists for the symptomatic alleviation of COPD. Therefore, there is considerable effort in discovering highly potent and selective β2-agonists.AREAS COVERED: Recent research on novel β2-agonists for the treatment of COPD. A detailed literature search was performed in two major databases (PubMed/MEDLINE and Scopus) up to September 2023."EXPERT OPINION: Compounds that preferentially activate a Gs- or β-arrestin-mediated signaling pat...
Source: Expert Opinion on Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Barbara Rinaldi Luigino Calzetta Paola Rogliani Mario Cazzola Source Type: research
Longitudinal efficacy of Ertugliflozin in type 2 diabetes: a meta-analysis of randomized controlled trials
CONCLUSION: Ertugliflozin showed clinical efficacy in improving glycemic control, fasting plasma glucose, body weight, and systolic blood pressure in T2DM patients over the studied time intervals compared to placebo.PMID:37955156 | DOI:10.1080/14656566.2023.2279100 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Parvej Khan Shubhashree Venkatesh Rizwana Parveen Pinki Mishra Seema Jain Nidhi Agarwal Source Type: research
Psychedelics for treatment resistant depression: are they game changers?
Expert Opin Pharmacother. 2023 Nov 10. doi: 10.1080/14656566.2023.2281582. Online ahead of print.ABSTRACTINTRODUCTION: A new era of treatment for adults with treatment-resistant depression (TRD), which involves psychedelic substances, is dawning. Emerging evidence indicates that psychedelics can exert antidepressant effects through multiple neurobiological and psychological mechanisms. However, it remains to be seen if these new treatments will revolutionize the treatment of TRD.AREAS COVERED: The present review focuses on the efficacy of classic serotoninergic psychedelics psilocybin, lysergic acid diethylamide (LSD), 5-M...
Source: Expert Opinion on Pharmacotherapy - November 10, 2023 Category: Drugs & Pharmacology Authors: Michail Kalfas Rosie H Taylor Dimosthenis Tsapekos Allan H Young Source Type: research
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
Expert Opin Pharmacother. 2023 Nov 9:1-4. doi: 10.1080/14656566.2023.2280630. Online ahead of print.NO ABSTRACTPMID:37942878 | DOI:10.1080/14656566.2023.2280630 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - November 9, 2023 Category: Drugs & Pharmacology Authors: Ashling Courtney Daranporn Triwongwarant Ivana Chim Samantha Eisman Rodney Sinclair Source Type: research
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
Expert Opin Pharmacother. 2023 Nov 9. doi: 10.1080/14656566.2023.2280630. Online ahead of print.NO ABSTRACTPMID:37942878 | DOI:10.1080/14656566.2023.2280630 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - November 9, 2023 Category: Drugs & Pharmacology Authors: Ashling Courtney Daranporn Triwongwarant Ivana Chim Samantha Eisman Rodney Sinclair Source Type: research
Correction
Expert Opin Pharmacother. 2023 Nov 8:1. doi: 10.1080/14656566.2023.2280342. Online ahead of print.NO ABSTRACTPMID:37937855 | DOI:10.1080/14656566.2023.2280342 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - November 8, 2023 Category: Drugs & Pharmacology Source Type: research
